Orexin OX₂ Receptor Antagonists as Sleep Aids

Area of Science:

• Neuroscience and Sleep Medicine
• Pharmacology of Sleep Disorders

Background:

• The orexin system is crucial for regulating arousal and sleep-wake cycles, with defects linked to narcolepsy.
• Orexin receptor antagonists, particularly dual orexin receptor antagonists (DORAs), are emerging treatments for insomnia.

Purpose of the Study:

• To review evidence comparing dual orexin receptor antagonists (DORAs) with selective OX2 receptor antagonists for insomnia treatment.
• To evaluate the potential of OX2 receptor antagonists in achieving more balanced sleep architecture compared to DORAs.

Main Methods:

• Review of preclinical (rodent) and clinical trial data (Phase I, II, III) for orexin receptor antagonists.
• Analysis of the effects of DORAs and OX2 receptor antagonists on sleep stages, including REM and NREM sleep.

Main Results:

• DORAs primarily increase REM sleep and can cause sleep onset REM (SOREM), an undesirable effect.
• Rodent studies indicate OX2 receptors are key targets for sleep modulation by orexin antagonists.
• Early clinical data for OX2 receptor antagonists suggest potential for balanced sleep induction and possibly lower narcolepsy risk.

Conclusions:

• Selective OX2 receptor antagonists may offer a superior or equivalent alternative to DORAs for insomnia, potentially providing more balanced sleep.
• Further clinical data is needed to confirm the efficacy and safety profile of OX2 receptor antagonists in insomnia patients.